The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus prednisone (Pred) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus Pred. The main questions it aims to answer are:
Does HCQ plus Pred raise the response rate in participants, compared to Pred alone? Does HCQ plus Pred prolong the response duration in participants, compared to Pred alone? What medical problems do participants have when taking HCQ plus Pred? Researchers will compare HCQ plus Pred with Pred alone to see if HCQ plus Pred works better to treat primary immune thrombocytopenia with positive anti-nuclear antibodies.
Participants will:
Take Pred every day for 6 weeks, with or without HCQ twice a day for 1 year , Visit the clinic once every 1 weeks for the first 4 weeks, and once every 2-4 weeks in the following 11 months for checkups and tests, Keep a diary of their symptoms.
Phase:
NA
Details
Lead Sponsor:
Yunfeng Cheng
Collaborators:
Dr. Stanley Ho Medical Foundation, Macau Health and Humanity Research Centre, Hongkong Macau University of Science and Technology Hospital Shanghai Jinshan Hospital Shanghai Zhongshan Hospital Zhongshan Qingpu Hospital, Fudan University Zhongshan Wusong Hospital, Fudan University